Advertisement
Advertisement
PROK
ProKidney Corp. Class A Ordinary Shares
1.86
USDSponsored
-0.02
-1.06%
May 08, 15:57 UTC -4
Closed
Pre-Market
1.90
+0.03
+1.88%
PROK Earnings Reports
Positive Surprise Ratio
PROK beat 11 of 14 last estimates.
79%
Next Report
Today
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$146.54K
/-$0.14
Implied change from Q4 25 (Revenue/ EPS)
-34.87%
/--
Implied change from Q1 25 (Revenue/ EPS)
-36.29%
/+7.69%
ProKidney Corp. Class A Ordinary Shares earnings per share and revenue
On Mar 18, 2026, PROK reported earnings of -0.14 USD per share (EPS) for Q4 25, missing the estimate of -0.12 USD, resulting in a -12.90% surprise. Revenue reached 225.00 thousand, compared to an expected 153.00 thousand, with a 47.06% difference. The market reacted with a -4.44% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.14 USD, with revenue projected to reach 146.54 thousand USD, implying an increase of 0.00% EPS, and decrease of -34.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were ProKidney Corp. Class A Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, ProKidney Corp. Class A Ordinary Shares reported EPS of -$0.14, missing estimates by -12.9%, and revenue of $225.00K, 47.06% above expectations.
How did the market react to ProKidney Corp. Class A Ordinary Shares's Q4 2025 earnings?
The stock price moved down -4.44%, changed from $2.25 before the earnings release to $2.15 the day after.
When is ProKidney Corp. Class A Ordinary Shares expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for ProKidney Corp. Class A Ordinary Shares's next earnings report?
Based on --
analysts, ProKidney Corp. Class A Ordinary Shares is expected to report EPS of -$0.14 and revenue of $146.54K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement